Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the European Commission has approved Boey® (trenibotulinumtoxinE) in Europe, for the temporary improvement in the appearance of moderate to severe lines between the eyebrows seen at maximum frown (glabellar lines) in adult patients, when these have an important psychological impact.1

Following completion of the centralized procedure, the European Commission decision applies across all 30 European Economic Area (EEA) countries. Boey® also received approval in Canada in June of this year.